To validate the significance of FADD/BID gene expression in T-cell based immunotherapies, we treated our cells with the CD38-directed monoclonal antibody daratumumab, which is commonly used in first-line treatment of MM. The gene discussed is CD38; the disease is Miyoshi myopathy.